Analysis of complete response by MRI following neoadjuvant chemotherapy predicts pathological tumor responses differently for molecular subtypes of breast cancer Corrigendum in /ol/5/4/1433

Hayashi,Yuji; Takei,Hiroyuki; Nozu,Satoshi; Tochigi,Yoshihiro; Ichikawa,Akihiro; Kobayashi,Naoki; Kurosumi,Masafumi; Inoue,Kenichi; Yoshida,Takashi; Nagai,Shigenori  E.; Oba,Hanako; Tabei,Toshio; Horiguchi,Jun; Takeyoshi,Izumi

doi:10.3892/ol.2012.1004

January 2013 Volume 5 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

January 2013 Volume 5 Issue 1

Full Size Image

Article

Analysis of complete response by MRI following neoadjuvant chemotherapy predicts pathological tumor responses differently for molecular subtypes of breast cancer

Corrigendum in: /ol/5/4/1433

Authors:
- Yuji Hayashi
- Hiroyuki Takei
- Satoshi Nozu
- Yoshihiro Tochigi
- Akihiro Ichikawa
- Naoki Kobayashi
- Masafumi Kurosumi
- Kenichi Inoue
- Takashi Yoshida
- Shigenori E. Nagai
- Hanako Oba
- Toshio Tabei
- Jun Horiguchi
- Izumi Takeyoshi
View Affiliations / Copyright

Affiliations: Division of Breast Surgery, Saitama Cancer Center, Saitama 362‑0806, Japan, Department of Radiology, Saitama Cancer Center, Saitama 362‑0806, Japan, Department of Pathology, Saitama Cancer Center, Saitama 362‑0806, Japan, Department of Breast Oncology, Saitama Cancer Center, Saitama 362‑0806, Japan, Department of Thoracic and Visceral Organ Surgery, Graduate School of Medicine, Gunma University, Gunma 371‑8511, Japan, Department of Thoracic and Visceral Organ Surgery, Graduate School of Medicine, Gunma University, Gunma 371‑8511, Japan
Pages: 83-89
|
Published online on: October 30, 2012

https://doi.org/10.3892/ol.2012.1004
Expand metrics +

Abstract

In the present study, clinical tumor response following neoadjuvant chemotherapy (NAC) was diagnosed by magnetic resonance imaging (MRI) and clinicopathological factors, including molecular subtypes at baseline, were analyzed for correlations with pathological tumor responses. In addition, clinicopathological factors were analyzed for a correlation with the MRI capacity to predict pathological complete response (pCR). Clinical tumor response evaluated by MRI following NAC was determined as a clinical CR (cCR) or a residual tumor. cCR was confirmed if no gadolinium enhancement or an enhancement equal to or less than that of glandular tissue was observed in any phase of the MRI. Pathological tumor responses following NAC were classified into grades 0 (no change) to 3 (no residual invasive cancer) according to criteria of the Japanese Breast Cancer Society. pCR was defined as grade 3 in the present study. Of 264 cases of invasive breast cancer in 260 patients (4 synchronous bilateral breast cancer cases), 59 (22%) were diagnosed by MRI following NAC as cCR and 98 (37%) were pathologically diagnosed as pCR. In terms of predicting pCR by MRI, the sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV) were 44, 90, 73, 73 and 73%, respectively. Tumor size, hormone receptor status, human epidermal growth factor receptor 2 (HER2) status, molecular subtype and histological type were significantly correlated with pathological tumor responses. pCR rates increased in the following order: luminal/HER2‑negative (14%), luminal/HER2‑positive (32%), triple‑negative (46%) and non‑luminal/HER2‑positive (73%) tumors. Sensitivity and specificity were the highest (60 and 100%, respectively) in triple‑negative tumors. PPV decreased in the following order: triple‑negative (100%), non‑luminal/HER2‑positive (92%), luminal/HER2‑positive (46%) and luminal/HER2‑negative (33%) tumors. In conclusion, MRI evaluation is useful for predicting pCR following NAC, particularly for triple‑negative tumors.

View Figures

View References

1	Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 16:2672–2685. 1998.PubMed/NCBI
2	Rastogi P, anderson SJ, Bear HD, et al: Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 26:778–785. 2008. View Article : Google Scholar : PubMed/NCBI
3	Symmans WF, Peintinger F, Hatzis C, et al: Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 25:4414–4422. 2007. View Article : Google Scholar : PubMed/NCBI
4	Smith IC, Heys SD, Hutcheon AW, et al: Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 20:1456–1466. 2002. View Article : Google Scholar : PubMed/NCBI
5	Buzdar AU, Valero V, Ibrahim NK, et al: Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 13:228–233. 2007.
6	Nakamura S: Present role and future perspectives of the evaluation of the effect of primary chemotherapy by breast imaging. Breast Cancer. 11:134–138. 2004. View Article : Google Scholar : PubMed/NCBI
7	Hylton N: MR imaging for assessment of breast cancer response to neoadjuvant chemotherapy. Magn Reson Imaging Clin N Am. 14:383–389. 2006. View Article : Google Scholar : PubMed/NCBI
8	von Minckwitz G, Untch M, Blohmer J-U, et al: Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 30:1796–1804. 2012.PubMed/NCBI
9	Kurosumi M, Akashi-Tanaka S, Akiyama F, et al: Histopathological criteria for assessment of therapeutic response in breast cancer (2007 version). Breast Cancer. 15:5–7. 2008. View Article : Google Scholar : PubMed/NCBI
10	Edge SB and Compton CC: The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
11	Chen JH, Fieg B, Agrawal G, et al: MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer. 112:17–26. 2008. View Article : Google Scholar : PubMed/NCBI
12	Chen JH, Bahri S, Mehta RS, et al: Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging. Radiology. 261:735–743. 2001. View Article : Google Scholar
13	Kuzucan A, Chen JH, Bahri S, et al: Diagnostic performance of magnetic resonance imaging for assessing tumor response in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy is associated with molecular biomarker profile. Clin Breast Cancer. 12:110–118. 2012. View Article : Google Scholar
14	McGuire KP, Toro-Burguete J, Dang H, et al: MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy? Ann Surg Oncol. 18:3149–3154. 2011. View Article : Google Scholar : PubMed/NCBI
15	De Los Santos J, Bernreuter W, Keene K, et al: Accuracy of breast magnetic resonance imaging in predicting pathologic response in patients treated with neoadjuvant chemotherapy. Clin Breast Cancer. 11:312–319. 2011.PubMed/NCBI
16	Woodhams R, Kakita S, Hata H, et al: Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging-comparison with contrast-enhanced MR imaging and pathological findings. Radiology. 254:357–366. 2010. View Article : Google Scholar